Clinical trial

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-12-03

PhasePHASE3

Study timeline

Study start (actual)2014-12-03Date precision: day

Registry last updated2020-11-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

OzanimodDRUG · verified · RxNorm: ozanimod

Interferon beta-1aDRUG · verified · RxNorm: interferon beta-1a

Placebo to ozanimodDRUG

Placebo to interferon beta-1aDRUG

Sponsors & collaborators

Celgenelead sponsor

Mapped research locations

SofiaBulgaria7 Saint PetersburgRussia6 MoscowRussia5 WarsawPoland4 BelgradeSerbia4 KatowicePoland4 ZagrebCroatia4 KharkivUkraine3 RigaLatvia3 TampaFlorida, United States2 BerlinGermany2 PhoenixArizona, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02294058 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.